Samuel Chima Ugbaja

Samuel Chima Ugbaja

Auto-generated profile, based on publicly available information

Samuel Chima Ugbaja

Traditional Medicine, School of Medicine, University of KwaZulu Natal, Durban 4000, South Africa

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2026 in Biochemistry Research International
Verified
Journal Article
Open access
RDReuben Samson Dangana
Reuben Samson Dangana
IEIsrael Ehizuelen Ebhohimen
Israel Ehizuelen Ebhohimen
SMSamson Anjikwi Malgwi
Samson Anjikwi Malgwi
SUSamuel Chima Ugbaja
Samuel Chima Ugbaja
MOMoses Okpeku
Moses Okpeku
Background: Malaria remains a significant and worldwide health threat with increasing resistance to current treatments, stimulating the demand for innovative approaches in pursuing drug discovery. This systematic review integrates the progress made from 2014 through 2024 regarding molecular methods like gene expression profiling, molecular docking and machine learning to understand the biology of Plasmodium and identify new drug targets and compounds, focusing on herbal remedies and computational methods. Methodology: Several studies were found using a PRISMA‐guided search of PubMed, Scopus and Web of Science (64 studies found). The data extracted were gene expression outcomes, docking affinities, ML models and experimental validations (in vitro/in vivo). Results: Molecular docking emerged as the dominant technique (32.37%), followed by in vitro antiplasmodial assays (14.39%), ADMET profiling (10.79%) and gene expression studies (3.60%). RNA‐seq analysis revealed key host and parasite genes modulated by herbal treatments, including those involved in apoptosis and inflammation. Notably, compounds like isorhamnetin and myricetin 3‐O‐glucoside showed exceptionally high binding affinities to Plasmepsin II and Plasmodium falciparum lactate dehydrogenase (PfLDH) (ΔG < −13 kcal/mol). ML models like random forest and support vector machine (SVM) exhibited high predictive results (AUC value up to 0.87) for bioactivity and resistance patterns that showed flavonoids (quercetin) and terpenoids (eugenol) as good candidates. Pathways that are often attacked are haemoglobin degradation, glycolysis, pyrimidine metabolism and protein synthesis. Conclusion: Multiomics, docking and ML integration improve the target identification and prioritise the compounds. This review illustrates the great potential of molecular techniques for the development of drugs against antimalarial helicases that are not resistant to drug therapy. However, in vivo data holes and methodology inconsistency limit clinical translation. Future work should include standardisation of protocols and studies of synergistic combinations of phytochemicals.

31 July 2023 in medRxiv
Verified
Preprint
Open access
PDF file
AMAGANZE GLOIRE-AIME MUSHEBENGE
AGANZE GLOIRE-AIME MUSHEBENGE
SUSamuel Chima Ugbaja
Samuel Chima Ugbaja
NMNonkululeko Avril Mbatha
Nonkululeko Avril Mbatha
MGManimani Riziki Ghislain
Manimani Riziki Ghislain
TMTambwe Willy Muzumbukilwa
Tambwe Willy Muzumbukilwa
HKHezekiel Kumalo
Hezekiel Kumalo
Background With the onset of the COVID-19 pandemic caused by the novel coronavirus (SARS-CoV-2), there has been a surge in the pursuit of potential therapeutic interventions for this deadly disease. Given the urgency of the situation, computational drug repurposing methods have emerged as a promising strategy for identifying effective treatments from a pool of approved drugs. This systematic review and meta-analaysis will assess the existing research on the use of computational approaches for drug repurposing in the context of COVID-19. SARS-CoV-2 Main Protease is a critical enzyme that plays a vital role in the replication cycle of the SARS-CoV-2 virus, and its inhibition is a promising strategy for the development of antiviral therapies. Methods/Design Different databases (PubMed, Cochrane Library, Cumulative Index to Nursing and Allied Health Literature (CINAHL), MEDLINE via EBSCOhost, Google Scholar, and WILEY online Library) will be utilized to identify and incorporate primary research articles in English and French that employed computational methodologies for drug repurposing in the context of COVID-19 and SARS-CoV-2 Main protease inhibition published between March 2020 to May 2023. According to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA-ScR), we will undertake a comprehensive search of relevant studies. Authors will also search peer-reviewed articles, grey literature sources, and reference lists to identify eligible studies. Title screening will be followed by independent abstract and full-text screening by two reviewers. Any study that focuses on the inhibition of the Mpro using computer aided methods will be included. The analysis of data will be carried out by utilizing two software tools - Review Manager software (version 5.3.5) and R software (version 3.6.1). To determine statistical heterogeneity, a standard chi-square test will be applied with a significance level of P < 0.10. Potential biases related to study size (such as publication bias) will be examined through the application of several techniques, including funnel plots, Egger’s test, Begg’s test, as well as Trim and Fill analysis. Discussion This study will provide evidence-based information and conduct a comprehensive analysis of the computer-aided drug discovery and repurposing of the SARS-CoV-2 Main protease inhibitors, thereby producing a high-quality synthesis of information. The study will also explore potential innovative therapeutic applications for preventing or treating the novel viral infection by the inhibition of the Main Protease. In addition, the review will highlight research gaps in the treatment of COVID-19 and provide suggestions for future research. The outcomes of this review will be shared through a peer-reviewed publication and presented at relevant conferences while ensuring proper dissemination to reach a wide audience. Systematic review registration: CRD42023409682 (https://www.crd.york.ac.uk/prospero/display_record.asp?ID=CRD42023409682)

30 April 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
SUSamuel Chima Ugbaja
Samuel Chima Ugbaja
MNMagugu Nkabinde
Magugu Nkabinde
NGNceba Gqaleni
Nceba Gqaleni
Background: The coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, remains a significant threat to global health. This continued threat is due to the emergence of new variants, the immune system’s limited ability to respond, and the limited effectiveness of available treatments for all individuals. Therefore, leveraging drug repurposing, a fast and inexpensive way to find other drugs that have already been shown to be safe and efficacious, becomes useful. This study leverages ADMET profiling, network pharmacology, and molecular docking to evaluate the repurposing of Product Nkabinde for COVID-19 treatment. Methods: ADMET analysis involving the bioactive phytochemicals of PN was evaluated for pharmacokinetic appropriateness and drug-likeness. Using topological analysis, a network of protein–protein interactions was built to identify hub genes, and predicted compound targets were intersected with COVID-19-associated genes to find shared targets. Their biological importance was characterized using functional enrichment analysis. The binding affinities of PN phytochemicals against hub proteins and SARS-CoV-2 viral proteases (Mpro and PLpro) were assessed by molecular docking using AutoDock Vina. To confirm docking accuracy, co-crystallized ligands were redocked using Schrodinger 2022-1. The multi-target therapeutic potential of PN in COVID-19 was assessed using this integrative network pharmacology and molecular docking technique. Results: Molecular docking demonstrated that PN phytochemicals displayed robust and persistent binding affinities for both viral and host targets. Oleanolic acid showed the best affinity toward Mpro (−12.9 kcal/mol vs. −8.3 kcal/mol), while quercetin-3-O-β-D-(6′-galloyl)-glucopyranoside showed better binding to PLpro (−8.4 kcal/mol vs. −6.4 kcal/mol). Procyanidin B2 toward HCK (−10.5 vs. −7.9 kcal/mol), diosgenin toward EGFR (−9.4 vs. −8.4 kcal/mol), rutin toward SRC (−10.5 vs. −7.8 kcal/mol), and pimelea factor P2 toward PIK3R1 (−11.0 vs. −8.2 kcal/mol) all showed significantly higher affinities than their corresponding co-crystallized ligands. Furthermore, procyanidin B2 demonstrated consistent binding to STAT1 and STAT3, confirming its role in modulating immune signals. Most of the PN phytochemicals show advantageous pharmacokinetic properties, including elevated anticipated gastrointestinal absorption and adherence to Lipinski’s rule of five, signifying favorable oral bioavailability and drug-like properties. Moreover, PN exhibits a remarkable multi-target binding capacity against both SARS-CoV-2 proteases and key host signaling proteins involved in immune regulation and inflammatory responses, as determined by this integrative network pharmacology and molecular docking investigation. Conclusions: PN’s prospects as a host-directed, antiviral treatment for COVID-19 are demonstrated by its coordinated modulation of the PI3K/AKT, JAK–STAT, SRC-family kinase, EGFR, and SYK pathways. These results necessitate further experimental and clinical validation, providing a solid computational basis for repurposing PN in the treatment of COVID-19.

16 April 2026 in Pharmaceuticals
Verified
Journal Article
Open access
SUSamuel Chima Ugbaja
Samuel Chima Ugbaja
MNMagugu Nkabinde
Magugu Nkabinde
NGNceba Gqaleni
Nceba Gqaleni
Background: Hepatitis B virus (HBV) infection continues to be a major public health concern, especially in sub-Saharan Africa, where widespread epidemics and restricted availability of long-term antiviral therapies result in higher mortality and morbidity rates. Drug repurposing represents a strategic approach to accelerate the discovery of effective therapies by leveraging agents with demonstrated antiviral and immunomodulatory activity. Product Nkabinde (PN) is a patented African polyherbal formulation initially developed for the treatment of HIV. Recent experimental studies demonstrate PN’s potent anti-HIV activity and significant immunomodulatory effects in human immune cells, implicating host-directed mechanisms relevant to chronic viral infections. This study combines an integrative application of network pharmacology and molecular docking to evaluate the repurposing potential of PN as a multi-target agent in HBV. Method: Bioactive components of PN were screened, and compound-associated targets were intersected with HBV-associated genes (proteins) to construct a protein–protein interaction (PPI) network. Topological analysis identified 10 hub targets (STAT1, STAT3, SRC, HCK, EGFR, SYK, PIK3CA, PIK3CB, PIK3R1, and PTPN11). Gene Ontology and KEGG pathway enrichment were performed with an FDR cut-off < 0.05. Significantly enriched pathways included JAK–STAT signaling, chemokine signaling, EGFR-TKI resistance, PI3K complex signaling, and viral infection pathways, particularly those related to Kaposi sarcoma virus and HSV-1, indicating immunoregulatory and antiviral roles. Molecular docking was performed using AutoDock Vina 1.1.2 to evaluate binding affinity and interaction mode of key PN phytochemicals against the hub proteins, and results were compared to their respective co-crystallized ligands. Results: Molecular docking indicated that major phytochemicals from PN exhibited significant binding affinities across all 10 hub host targets, typically outperforming or closely matching their respective co-crystallized ligands. The strongest contacts were observed for β-sitosterol–PIK3CB (−14.2 kcal/mol) and oleanolic acid–SYK (−14.0 kcal/mol), which were significantly stronger than the co-crystallized ligands (−7.9 and −8.3 kcal/mol, respectively), indicating robust stabilization within catalytic and regulatory pockets. Procyanidin B2 toward HCK (−10.5 vs. −7.9 kcal/mol) and PIK3CA (−9.5 vs. −7.3 kcal/mol), quercetin toward PIK3R1 (−10.6 vs. −8.2 kcal/mol) and PTPN11 (−9.2 vs. −7.5 kcal/mol), rutin toward SRC (−10.5 vs. 7.8 kcal/mol), and diosgenin toward EGFR (−9.4 vs. 8.4 kcal/mol). Procyanidin B2 maintained robust multi-hydrogen bonding networks, demonstrating significant binding, despite STAT1 and STAT3 docking showing identical affinities to co-crystals. Conserved hydrogen bonds, π–cation interactions, and significant hydrophobic packing at ATP-binding clefts and regulatory domains supported these interaction patterns, indicating competitive suppression of host signaling nodes taken over by HBV. Conclusions: Together, these results demonstrate that the components of PN possess strong multitarget binding capabilities across the PI3K/AKT, JAK–STAT, SRC-family kinase, EGFR, and SYK pathways, supporting their potential repurposing as host-directed HBV therapeutics with the ability to impede immune evasion, viral persistence, and HBV-associated oncogenic progression.

5 August 2023 in medRxiv
Verified
Preprint
Open access
PDF file
AMAGANZE GLOIRE-AIME MUSHEBENGE
AGANZE GLOIRE-AIME MUSHEBENGE
SUSamuel Chima Ugbaja
Samuel Chima Ugbaja
NMNonkululeko Avril Mbatha
Nonkululeko Avril Mbatha
MGManimani Riziki Ghislain
Manimani Riziki Ghislain
TMTambwe Willy Muzumbukilwa
Tambwe Willy Muzumbukilwa
HKHezekiel Kumalo
Hezekiel Kumalo
Introduction: COVID-19 is a rapidly spreading infectious disease caused by the SARS-CoV-2 virus. Although several therapeutic interventions have been developed, the mortality rate of the disease remains high, and effective treatment options are urgently needed. Host-directed therapies targeting enzymes involved in the immune response represent a promising strategy for the development of novel therapeutics against COVID-19. This study aims to conduct a systematic review and meta-analysis of the literature to evaluate the potential of drug candidates targeting host enzymes involved in the immune response for the treatment of COVID-19. Methods and analysis: We will conduct a systematic search of electronic databases including PubMed, Embase, and Cochrane Library, as well as preprint servers and clinical trial registries for relevant studies. We will include randomized controlled trials, observational studies, and preclinical studies evaluating the efficacy of drug candidates targeting host enzymes involved in the immune response in COVID-19. Two reviewers will independently screen articles, extract data, and assess study quality. The primary outcome will be the effect of drug candidates on mortality, while secondary outcomes will include time to recovery, adverse events, and changes in immune markers. A meta-analysis will be performed to estimate pooled effect sizes of the interventions, and a narrative synthesis will be conducted for studies that are not amenable to quantitative analysis. This study will provide a comprehensive evaluation of the potential of host-directed therapies targeting enzymes involved in the immune response for the treatment of COVID-19. The results of this study may guide the development of novel therapeutics against COVID-19 and inform clinical practice. Ethics and dissemination: This study will review published data, and thus it is unnecessary to obtain ethical approval. The findings of this systematic review will be published in a peer-reviewed journal. PROSPERO registration number: CRD42023415110 .

17 November 2026 in Plastic Surgery / Chirurgie Plastique
Verified
Journal Article
Open access
PAPeterson Atiba
Peterson Atiba
OAOkikioluwa Stephen Aladeyelu
Okikioluwa Stephen Aladeyelu
SUSamuel Chima Ugbaja
Samuel Chima Ugbaja
AMAnil Madaree
Anil Madaree
LLLelika Lazarus
Lelika Lazarus
Background: Tessier craniofacial clefts arise from the failure of fusion of embryonic facial prominences or disruption in the mesodermal penetration of prominences. They are classified as midline (MTC), paramedian or lateral Tessier clefts. This study aimed to investigate the morphologic and anthropometric features of Tessier clefts 0, 14 and 30 that currently exist in the literature. Furthermore, parameters that guide surgical interventions and clinical outcomes are reviewed and reported. Methods: In October 2025, a comprehensive literature search was conducted in PubMed, EBSCOhost and Scopus to identify studies exploring the morphology and anthropometry of the median Tessier clefts. Eligible studies underwent a risk-of-bias (ROB) assessment using the mixed methods appraisal tool for validation, and the findings were synthesised narratively. Results: Eighteen studies fulfilled the inclusion criteria, representing a total of 313 patients (55% male, 45% female). Most studies originated from upper-middle-income countries (56%), followed by high-income (22%) and low-income (17%) settings; while 5% remained unspecified. All studies (100%) described morphological features, whereas only 3 (17%) provided anthropometric data. Primary surgical reconstruction was typically performed between 0.1 and 9 years of age, with definitive procedures deferred until skeletal maturity. Assessment of ROB revealed high quality for all the included studies. Conclusion: Although morphological descriptions of MTC are well represented in the literature, anthropometric data remain scarce, and their systematic application in surgical planning is limited. Greater incorporation of objective anthropometric measurements is needed to improve reproducibility, outcome evaluation and eventual standardisation of reconstructive strategies for these challenging craniofacial anomalies.